[go: up one dir, main page]

PE20120921A1 - Compuestos eteres aralquil bencilicos, proceso de preparacion de los mismos, compuestos intermediarios, composicion farmaceutica y medicamento que contiene dichos compuestos - Google Patents

Compuestos eteres aralquil bencilicos, proceso de preparacion de los mismos, compuestos intermediarios, composicion farmaceutica y medicamento que contiene dichos compuestos

Info

Publication number
PE20120921A1
PE20120921A1 PE2012000254A PE2012000254A PE20120921A1 PE 20120921 A1 PE20120921 A1 PE 20120921A1 PE 2012000254 A PE2012000254 A PE 2012000254A PE 2012000254 A PE2012000254 A PE 2012000254A PE 20120921 A1 PE20120921 A1 PE 20120921A1
Authority
PE
Peru
Prior art keywords
compounds
pharmaceutical composition
preparation process
same
benzyl
Prior art date
Application number
PE2012000254A
Other languages
English (en)
Inventor
Artur Franz Keppler
Sergio Luiz Sacurai
Marcio Henrique Zaim
Carlos Eduardo Da Costa Touzarim
Original Assignee
Biolab Sanus Farmacêutica Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43627099&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120921(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biolab Sanus Farmacêutica Ltda filed Critical Biolab Sanus Farmacêutica Ltda
Publication of PE20120921A1 publication Critical patent/PE20120921A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C22/00—Cyclic compounds containing halogen atoms bound to an acyclic carbon atom
    • C07C22/02—Cyclic compounds containing halogen atoms bound to an acyclic carbon atom having unsaturation in the rings
    • C07C22/04—Cyclic compounds containing halogen atoms bound to an acyclic carbon atom having unsaturation in the rings containing six-membered aromatic rings
    • C07C22/08—Cyclic compounds containing halogen atoms bound to an acyclic carbon atom having unsaturation in the rings containing six-membered aromatic rings containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

REFERIDA A UN DERIVADO ARAQUILBENCILICO DE FORMULA (I), DONDE Ar ES ARILO, IMIDAZOLILO, 1,2,4-TRIAZOLILO O BENCIMIDAZOLILO; R1, R2, R4 Y R5 SON H, HALOGENO, ALQUILO C1-C6; R3 ES HALOGENO, ALQUILO C1-C6; n Y m SON UN ENTERO DE 0 A 5. SON COMPUESTOS PREFERIDOS: 1-[2-(2,4-DICLOROFENIL)-2-{[4-(TRIFLUOROMETIL)BENCIL]OXI}ETIL]-1H-IMIDAZOL, 1-[2-(2,4-DICLOROFENIL)-2-({4-[(2-FENIL)-2H-TETRAZOL]BENCIL}OXI)ETIL]-1H-IMIDAZOL, 1-[2-(BIFENIL-4-ILMETOXI)-2-(2,4-DICLOROFENIL)ETIL]-1H-IMIDAZOL, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES CAUSADAS POR MICROORGANISMOS TALES COMO HONGOS, BACTERIAS Y/O PROTOZOARIOS
PE2012000254A 2009-08-28 2010-08-27 Compuestos eteres aralquil bencilicos, proceso de preparacion de los mismos, compuestos intermediarios, composicion farmaceutica y medicamento que contiene dichos compuestos PE20120921A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0904249-0A BRPI0904249B1 (pt) 2009-08-28 2009-08-28 Compostos éteres aralquil benzílicos, processo de preparação dos mesmos, uso dos referidos compostos, composição farmacêutica

Publications (1)

Publication Number Publication Date
PE20120921A1 true PE20120921A1 (es) 2012-08-01

Family

ID=43627099

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000254A PE20120921A1 (es) 2009-08-28 2010-08-27 Compuestos eteres aralquil bencilicos, proceso de preparacion de los mismos, compuestos intermediarios, composicion farmaceutica y medicamento que contiene dichos compuestos

Country Status (24)

Country Link
US (1) US8975289B2 (es)
EP (1) EP2471781B1 (es)
JP (1) JP5718334B2 (es)
KR (1) KR101765752B1 (es)
CN (1) CN102625800A (es)
AR (1) AR078115A1 (es)
AU (1) AU2010286266B2 (es)
BR (1) BRPI0904249B1 (es)
CA (1) CA2771044C (es)
CL (1) CL2012000463A1 (es)
DK (1) DK2471781T3 (es)
ES (1) ES2606168T3 (es)
HU (1) HUE032199T2 (es)
IL (1) IL218044A (es)
IN (1) IN2012DN00611A (es)
MX (1) MX2012002276A (es)
PE (1) PE20120921A1 (es)
PL (1) PL2471781T3 (es)
PT (1) PT2471781T (es)
RU (1) RU2548009C2 (es)
SG (1) SG178298A1 (es)
UA (1) UA108479C2 (es)
WO (1) WO2011022798A1 (es)
ZA (1) ZA201201442B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102579829B (zh) * 2012-03-06 2013-09-18 康莉 一种治疗牛放线菌病的中药组合物及其制备方法
CN104016837B (zh) * 2014-05-26 2016-08-24 武汉有机实业有限公司 4,4’-二甲基二苄基醚的制备方法
RU2603622C1 (ru) * 2015-06-25 2016-11-27 Федеральное государственное бюджетное научное учреждение "Прикаспийский зональный научно-исследовательский ветеринарный институт" Комплексный метод лечения тейлериоза мелкого рогатого скота
CN108047147A (zh) * 2017-12-08 2018-05-18 长江大学 一类三唑类化合物以及作为杀菌剂的用途
KR101983575B1 (ko) * 2017-12-21 2019-06-03 대한민국 신균주 세라토바시디움 속 js1289 및 이의 용도
JP7583027B2 (ja) * 2019-08-16 2024-11-13 パーデュー・リサーチ・ファウンデーション プロテアソームのコア粒子の低分子刺激物質
JP2023057423A (ja) * 2021-10-11 2023-04-21 国立大学法人 熊本大学 ムコール症治療薬

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1170188A (en) 1967-09-15 1969-11-12 Bayer Ag N-trityl-imidazoles and salts and uses thereof
SU557755A3 (ru) * 1968-08-19 1977-05-05 Янссен Фармасьютика Н.В. (Фирма) Способ получени производных имидазола
DE2333354C2 (de) * 1973-06-30 1983-12-15 Bayer Ag, 5090 Leverkusen 2-Aryloxy-2-(imidazol-1-yl)-äthanole sowie deren Salze, Verfahren zu ihrer Herstellung und ihre Verwendung als Fungizide
GB1475271A (en) 1975-04-30 1977-06-01 Pfizer Ltd 1-aryl-2-1-imidazolyl-alkyl ethers and thioethers and their use as antifungal agents
DE2556319A1 (de) * 1975-12-13 1977-06-23 Basf Ag Substituierte triazol-aether
US4144346A (en) 1977-01-31 1979-03-13 Janssen Pharmaceutica N.V. Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles
US4218458A (en) 1978-06-23 1980-08-19 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-aryloxy-methyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4277475A (en) * 1979-01-11 1981-07-07 Syntex (U.S.A.) Inc. Contraceptive methods employing 1-substituted imidazole derivatives
BE885957A (nl) 1980-10-31 1981-04-30 Amylum Graanderivaten Raff Inrichting voor de continue bereiding van zetmeellijm
US4368186A (en) 1981-05-07 1983-01-11 Syntex (U.S.A.) Inc. Methods and compositions for intravaginal contraception
DE3314738A1 (de) * 1983-04-23 1984-10-25 Bayer Ag, 5090 Leverkusen Azolylethyl-benzyl-ether-derivate, verfahren zu ihrer herstellung und ihre verwendung als fungizide
US5278175A (en) 1990-02-02 1994-01-11 Pfizer Inc. Triazole antifungal agents
JP2875140B2 (ja) * 1993-08-16 1999-03-24 明治製菓株式会社 抗ｍｒｓａ組成物
US5461068A (en) * 1993-09-29 1995-10-24 Corwood Laboratories, Inc. Imidazole derivative tincture and method of manufacture
US5750147A (en) 1995-06-07 1998-05-12 Emisphere Technologies, Inc. Method of solubilizing and encapsulating itraconazole
US20060194769A1 (en) * 2005-01-25 2006-08-31 University Of Vermont And State Agricultural College Small molecules that reduce fungal growth
WO2006082588A2 (en) * 2005-02-07 2006-08-10 Pharmalight Inc. Method and device for ophthalmic administration of active pharmaceutical ingredients
GB0714226D0 (en) * 2007-07-20 2007-08-29 Therapeutics Ltd E anti-bacterial combination therapy
GB0724996D0 (en) * 2007-12-21 2008-01-30 Therapeutics Ltd E Antibacterial combination therapy for the treatment of gram positive bacterial infections
GB0813211D0 (en) * 2008-07-18 2008-08-27 E Therapeutics Plc Antibacterial combination therapy for the treatment of gram positive bacterial infections
WO2010025459A2 (en) * 2008-08-29 2010-03-04 The Uab Research Foundation Novel anti-arrhythmia agent

Also Published As

Publication number Publication date
BRPI0904249A2 (pt) 2011-05-17
CA2771044C (en) 2017-07-04
US20120196908A1 (en) 2012-08-02
IN2012DN00611A (es) 2015-06-12
RU2548009C2 (ru) 2015-04-10
ES2606168T3 (es) 2017-03-23
MX2012002276A (es) 2012-04-19
IL218044A (en) 2017-02-28
KR20120050490A (ko) 2012-05-18
CN102625800A (zh) 2012-08-01
AU2010286266B2 (en) 2015-02-12
JP5718334B2 (ja) 2015-05-13
EP2471781A4 (en) 2013-01-23
WO2011022798A1 (pt) 2011-03-03
KR101765752B1 (ko) 2017-08-07
HUE032199T2 (en) 2017-08-28
PT2471781T (pt) 2016-12-15
EP2471781B1 (en) 2016-09-07
SG178298A1 (en) 2012-03-29
RU2012110925A (ru) 2013-10-10
DK2471781T3 (da) 2017-01-02
PL2471781T3 (pl) 2017-08-31
CL2012000463A1 (es) 2012-09-21
ZA201201442B (en) 2012-10-31
EP2471781A1 (en) 2012-07-04
BRPI0904249B1 (pt) 2018-03-06
AU2010286266A1 (en) 2012-04-05
AR078115A1 (es) 2011-10-12
US8975289B2 (en) 2015-03-10
IL218044A0 (en) 2012-04-30
UA108479C2 (en) 2015-05-12
CA2771044A1 (en) 2011-03-03
JP2013503111A (ja) 2013-01-31

Similar Documents

Publication Publication Date Title
PE20120921A1 (es) Compuestos eteres aralquil bencilicos, proceso de preparacion de los mismos, compuestos intermediarios, composicion farmaceutica y medicamento que contiene dichos compuestos
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
PE20130385A1 (es) Derivados del acido naft-2-ilacetico para tratar el sida
MX2012004089A (es) Inhibidores de hsp90.
NZ599513A (en) Compounds for the treatment of dyslipidemia and related diseases
MX2010006421A (es) Compuestos organicos.
MX2012013274A (es) Novedosos derivados de la pirimidina.
PE20090952A1 (es) Compuestos de pirazol moduladores de raf
NZ607381A (en) 5-iodo-triazole derivatives
NZ622769A (en) Benzothiazol-6-yl acetic acid derivatives and their use for treating an hiv infection
MA37405A1 (fr) Composés hétérocyclyle
GEP20146125B (en) Aminopyrimidines as syk inhibitors
PE20091828A1 (es) Derivados de acido ciclopentanocarboxilico condensados sustituidos con acilamino como inhibidores de edg-2
MX2009012390A (es) Uso de compuestos de 4-(pirrolidin-1-il)quinolina para exterminar microorganismos clinicamente latentes.
MX2011012337A (es) Nuevos derivados de pirimidina y su uso en el tratamiento de cancer y de otras enfermedades.
TN2014000033A1 (fr) Indazoles
PE20120355A1 (es) DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1
PE20090243A1 (es) Compuestos de imidazol sustituido como inhibidores de renina
PE20141408A1 (es) Aminoquinazolinas como inhibidores de quinasa
BR112013003439A2 (pt) "inibidores de oxadiazol de produção de leucotrieno"
EA201070588A1 (ru) Производные 1,2,3-триазола для применения в качестве ингибиторов стеароил-соа десатуразы
PE20140966A1 (es) Quinazolincarboxamida azetidinas
MA32929B1 (fr) Lactames en tant qu'inhibiteurs de bêta-sécrétase
ATE473221T1 (de) 1-(1-benzylpiperidin-4-yl)benzimidazol-5- carbonsäurederivate zur behandlung von diabetes mellitus
NZ592314A (en) Sulfoximine-substituted anilinopyrimidine derivatives as cdk inhibitors, the production thereof, and use as medicine

Legal Events

Date Code Title Description
FG Grant, registration